Related Experiment Videos

Critical evaluation of the efficacy and tolerability of azilsartan

Alberto R De Caterina1, Andrew R Harper, Florim Cuculi

  • 1Istituto Scienze della Vita, Scuola Superiore Sant'Anna, Pisa, Italy. adecatro@yahoo.it

Vascular Health and Risk Management
|June 5, 2012
PubMed

Insights

Achieving blood pressure control in hypertension remains challenging. Azilsartan medoxomil, a new angiotensin receptor blocker, is reviewed for its efficacy and safety in managing high blood pressure.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Nephrology

Background:

  • Hypertension management remains a critical therapeutic goal, with many patients failing to reach target blood pressure (BP) levels below 140/90 mmHg despite available treatments.
  • The persistent gap in achieving BP control necessitates the development of novel antihypertensive agents.
  • The introduction of new drugs aims to improve therapeutic outcomes for hypertensive individuals.

Purpose of the Study:

  • To evaluate the efficacy and safety profile of azilsartan medoxomil, a novel angiotensin receptor blocker.
  • To review existing pre-clinical and clinical data on azilsartan medoxomil for blood pressure management.
  • To provide a comprehensive overview of this new agent for clinical practice.

Main Methods:

  • Systematic review of pre-clinical studies investigating the pharmacological actions of azilsartan medoxomil.
  • Analysis of clinical trial data assessing the efficacy of azilsartan medoxomil in hypertensive patients.
  • Safety data evaluation from post-marketing surveillance and clinical studies.

Main Results:

  • Azilsartan medoxomil demonstrates significant BP-lowering effects in hypertensive patients.
  • The compound exhibits a favorable safety profile with a low incidence of adverse events.
  • Comparative studies indicate comparable or superior efficacy to existing antihypertensive therapies.

Conclusions:

  • Azilsartan medoxomil represents a valuable new option for hypertension treatment, offering effective BP control.
  • Its efficacy and safety profile support its use in achieving therapeutic BP targets.
  • Further research may elucidate its long-term benefits and role in diverse hypertensive populations.

Keywords:
angiotensin receptor blockerazilsartan medoxomilhypertension

Related Concept Videos

Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...